|
08 Feb 2016 |
Social |
Acute sacroiliitis Dx by bone or CT scan. Causes include pyogenic infx, brucellosis, crystal induced, neoplasia https://t.co/toLl8suM0i |
|
|
20 Nov 2019 |
Social |
@uptoTate PLENARY: COAST-X: IXE met ASAS 40 and all secondary endpoints in nr-axSpA vs PBO. https://t.co/mfTTMaCgWg #ACR19 Abst #2729 https://t.co/qaEi39JFPp |
|
|
23 Oct 2016 |
Social |
Dr. Sergio Schwartzman comments on new Ocular Screening Guidlines for Hydroxychloroquine at RheumNow https://t.co/Qm1iDM77Jo |
|
|
18 Jul 2017 |
Social |
320 pt Rheum-Derm clinic in Vancouver - lupus is most common rheum dx; dermatitis & psoriasis most common Derm Dx https://t.co/soA3UXsfXF |
|
|
07 Nov 2017 |
Social |
RT @Janetbirdope: #GAMECHANGER. Ankylosing spondylitis genetics are biased AS parent is more likely to have AS in sons #acr17 @rheumnow #1 |
|
|
14 Jun 2018 |
Social |
RT @DrPetryna: #EULAR18 @RheumNow ABST thu0297 CVRF higher in PSO, PsA & periph SpA w/o PSO comparing to gen pop but similar amongst the Dx… |
|
|
17 Jun 2019 |
Social |
RT @tuna0sashimi: FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. S… |
|
|
19 Feb 2018 |
Social |
2018 AAD presentations on upadacitinib (Abbvies JAK1 inhibitor) shows it effective in reducine pruritus, with rapid responses in psoriasis by Week. Also under study for atopic dermatitis and more. https://t.co/6c4yauVPCC |
|
|
04 Jan 2017 |
Social |
NICE recommends apremilast for use in psoriatic arthritis w/in UK NHS. Risk of suidical ideation is 0.2% (3/1441) https://t.co/ZFDSo3B81u |
|
|
29 Sep 2017 |
Social |
Higher MASEI (enthesitis) scores in PsA assoc w/ more Jt damage, ankylosis, arthritis mutilans periostitis, axial Dz https://t.co/NKw37wkka5 |
|
|
07 Nov 2017 |
Social |
RT @Lupusdoc: Poster title of the day....! #2556 @RheumNow #ACR17 https://t.co/nDmsAQQS19 |
|
|
13 Jan 2019 |
Social |
QD Video on RheumNow - an HLA-B27+ patient with Iritis, Enthesitis, Diarrhea. https://t.co/LusZttdAyw |
|
|
02 Jul 2015 |
Social |
Ixekizumab (anti-IL17) is superior to Enbrel in 1224 pts w/ plaque psoriasis (UNCOVER-2) w/ rapid decr in itch scores http://t.co/ozZbHEq6Wu |
|
|
17 Feb 2017 |
Social |
RT @DrRachelTate: Tofa as an option for AS? No FDA indication but a potential off label option. E. Ruderman MD #rwcs2017 @RWCSmtg @RheumNow… |
|
|
16 Oct 2017 |
Social |
Population survey found psoriasis/PsA in 1.4-3.3%; Nearly 1/2 not seeing MD or stopped biologic for safety/no effect https://t.co/JGHWuIUacK |
|
|
08 Jun 2016 |
Social |
Secukinumab data presented at EULAR; Novartis plans H2H trial of Cosentyx & Humira; details to follow https://t.co/zjA8Rgw0cX |
|
|
13 Feb 2020 |
Social |
1st Jan inhibitor in AS - upadacitinib, it works! Drs Ruderman/Kavanaugh #RWCS2020 @RWCSmtg https://t.co/KLJh43h7pz |
|
|
08 Nov 2017 |
Social |
RT @_connectedcare: Lots of different causes for Red Eye in autoimmune arthritis. Here’s a list #ACR17 @RheumNow https://t.co/pMi2tLMDpk |
|
|
30 Sep 2019 |
Social |
Tofacitinib therapy is being studied (not yet approved) in several dermatologic conditions - psoriasis, alopecia areata/universalis, vitiligo, atopic dermatitis and dermatomyositis. https://t.co/Ez3u95Eh7K |
|
|
11 Nov 2019 |
Social |
RT @EBRheum: RCT Tildrakizumab (IL23i) in Psoriatic Arthritis
Beat PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% imp… |
|
